Thorell Marella 4
4 · Seres Therapeutics, Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
Seres Therapeutics (MCRB) CFO Thorell Marella Receives 7,500-Unit Award
What Happened
Thorell Marella, EVP and Chief Financial Officer of Seres Therapeutics (MCRB), was granted 7,500 derivative awards on July 8, 2026. The filing reports an acquisition price of $0.00 and a reported value of $0 for the grant (derivative instrument). This was a compensation award (grant), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-07-08; Form 4 filed: 2026-07-10 (filed two days after the transaction).
- Instrument: Derivative award (described in filing as an option) for 7,500 units at $0.00 (reported value $0).
- Vesting: 25% of the award vests on March 2, 2027; the remainder vests in 12 equal quarterly installments thereafter (see footnote).
- Shares owned after the transaction: Not specified in the filing.
- Filing timeliness: Report appears timely (filed within two days of the transaction).
Context
This is a grant of a derivative compensation award (an option-style award) that will vest over time; Marella does not immediately own tradable shares from this grant. Such grants are routine executive compensation and do not by themselves indicate buying or selling sentiment in the open market.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-07-08+7,500→ 7,500 totalExercise: $9.13Exp: 2036-03-03→ Common Stock (7,500 underlying)
Footnotes (1)
- [F1]The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter.